Not Financial Advice TL;DR Bullish Pennant on BINANCE:ETHUSDT daily chart, upwards breakout target would be very close to 2021 ATH. SEC approval of VanEck ETF (final deadline on May 23) could be a major catalyst. A rare case of (potential) technical and fundamental confluence: ETH has been building a Bullish Pennant since the end of the Feb 5 - Mar 12...
Hello TradingView Family / Fellow Traders, As per my last analysis, ETH rejected the $3000 support and traded higher. What's next? Scenarios: 1️⃣ Bullish - Continuation For the bulls to maintain control, a break above the $4,000 - $4,100 is needed. In this case, a movement towards the $4,500 resistance would be expected. 2️⃣ Bearish - Correction...
In this chart, BINANCE:LDOUSDT surpasses its previous ATH of $0.389 and currently around that price. What would be the next potential resistance to watch. I'll provide a technical analysis in the comment threads below.
The price of Ethereum (ETH) will be affected by the approval of the Bitcoin ETF this week. Some of the biggest asset managers on the entire planet are going to release a BTC ETF: Blackrock $9.3 Trillion Fidelity $4.5 Trillion Franklin Templeton $1.53 trillion Invesco $1.5 Trillion. BlackRock expects Bitcoin ETF approval on Wednesday, in-line with Bloomberg's...
Traders, A few posts ago, you will see that (2) two gaps were being focused on. The question was posed about which might be filled first. Many of my followers understand that my bias was to the upside gap being filled first. Thanks to the Blackrock ETF approval, this has occurred. And, as I stated in my video yesterday, I have unloaded 50% of ALL my positions...
A multi-year trend analysis to see if upcoming catalyst will push upward momentum past current resistance highs.
Bio-Path released updated Phase 2 data for its lead candidate prexigebersen, codenamed BP1001, for treating acute myeloid leukemia, or AML, and also divulged a plan of action for taking the compound through clinical development toward registration. Updated data from the Stage 1 of the Phase 2 study that evaluated the efficacy and safety of prexigebersen in...
Upcoming FDA decision and Fib retracement